News

Molecular Partners and Novartis Report Positive Topline Data from Phase 2 Study for Ensovibep (MP0420), a DARPin Antiviral Therapeutic for COVID-19

News 10.01.2022 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR: Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, and Novartis today announced that Part A of the...

read more

Molecular Partners Announces Collaboration with Novartis to Develop DARPin-Conjugated Radioligand Therapeutic Candidates for Oncology

News 14.12.2021 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR: Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced a collaboration with Novartis in the form of a...

read more

Molecular Partners Confirms Ensovibep Retains Neutralization of Omicron Variant of SARS-CoV-2 in Preclinical Studies

News 13.12.2021 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 12, 2021 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR: Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that preclinical studies confirm that ensovibep maintains...

read more

Molecular Partners Announces Research Collaboration with University of Bern to Develop MP0533, a Multispecific DARPin for the Treatment of AML

News 03.12.2021 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 03, 2021 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced a research collaboration with University of Bern, to advance the development of the Company’s wholly...

read more